MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA), a leader in soft tissue reconstruction innovations, has announced the appointment of Jeffrey Blizard as its new President, effective immediately. Blizard, who has been a member of TELA Bio’s Board of Directors for the past year, brings a wealth of experience and a proven track record of leadership in the medtech industry.
“This is an important inflection point for TELA Bio,” said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. “As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected leader with a track record of scaling businesses and inspiring teams—will amplify our ability to compete and win in a dynamic market. We are confident that this leadership evolution will drive meaningful commercial performance and reinforce our commitment to delivering exceptional value to our customers, partners, and shareholders.”
Extensive Experience in Medtech
Blizard comes to TELA Bio from Abiomed, a Johnson & Johnson company, where he served as Global Head of Surgical Sales. During his tenure, he significantly expanded the Surgical Division’s performance, driving sustained growth over multiple years.
His distinguished career also includes senior commercial roles at prominent medtech companies such as Medtronic, Intuitive Surgical, and Boston Scientific. Blizard’s background reflects extensive experience in building and scaling commercial operations within competitive markets, skills that are expected to play a key role in TELA Bio’s ongoing growth.
Vision for Leadership
Blizard expressed enthusiasm for stepping into his new role and working to advance TELA Bio’s strategic goals. “TELA Bio has built an extraordinary foundation and a differentiated portfolio that is redefining soft tissue reconstruction,” he said. “I’m thrilled to join a mission-driven team with such momentum and look forward to working alongside our talented leadership and commercial teams to accelerate execution, deepen customer relationships, and scale our impact.”
Strengthening Market Position
The appointment underscores TELA Bio’s ambition to enhance its commercial capabilities and secure its position as a leading innovator in the soft tissue reconstruction market. With Blizard’s leadership and deep sector expertise, the company aims to strengthen relationships with customers and partners, while driving growth and delivering shareholder value.
TELA Bio’s management expressed confidence that these strategic developments align with the company’s long-term vision of delivering cutting-edge solutions tailored to meet the diverse needs of clinicians and patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.